Evolocumab Value Chain Analysis & Forecast Outlook 2033

Evolocumab by Application (Chemical, Pharmaceutical), by Types (Patent, Generic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Evolocumab Market Size | CAGR 7.2 Forecast 2033

Evolocumab Value Chain Analysis & Forecast Outlook 2033

Evolocumab by Application (Chemical, Pharmaceutical), by Types (Patent, Generic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Evolocumab Market Overview

Evolocumab, marketed as Repatha, is a monoclonal antibody PCSK9 inhibitor used to lower LDL‑cholesterol in patients with familial hypercholesterolemia and atherosclerotic cardiovascular disease. Its clinical efficacy and guideline endorsement make it a cornerstone of modern lipid‑management therapy. The Evolocumab market size was estimated at approximately $3.6 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of ~7.5% from 2026 to 2033, driven by rising prevalence of cardiovascular disease, expanding insurance coverage, and increasing adoption of value‑based contracts. Key forces shaping the industry include heightened regulatory scrutiny and reimbursement reforms, intensifying competition from alirocumab and emerging biosimilar PCSK9 inhibitors, and a shift toward personalized, outcome‑based therapy models. North America remains the largest market, while the Asia‑Pacific region is emerging as the fastest‑growing segment.

Loading chart…

The growth outlook reflects a convergence of macro‑economic and clinical trends: aging demographics, escalating lipid‑screening programs, and robust real‑world evidence of cardiovascular risk reduction. Competitive intensity is sharpening as alirocumab seeks market share and the first PCSK9 biosimilars are expected to launch in Europe and Asia by 2027, pressuring pricing and prompting manufacturers to pursue differentiated delivery devices and combination regimens. Supply‑chain resilience, particularly in biologics manufacturing, remains a strategic priority, with firms investing in regional fill‑finish sites to support the rapid expansion of the Asia‑Pacific market, which is projected to outpace global growth rates by 2029.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	9.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BOCSCI; Carbosynth; TargetMol Chemicals; Chemren Bio-Engineering; DC Chemicals; Hefei Enli Medical Technology; Hefei Hirisun Pharmatech; Hubei Kele Fine Chemical; Hubei Xingcheng Biotechnology; Hubei Zhongshan Medical Technology; Nantong Feiyu Biological Technology; Nantong Hi-Future Biotechnology; Shanghai Biochempartner; Shanghai Loulan Biotechnology; Shanghai Macklin Biochemical; Shanghai Minkai Biotechnology; Shanghai Ruihui Chemical Technology; Shanghai Yifei Biotechnology; Sichuan Weiqi Biotechnology; Taizhou KEDE Chemical; Taizhou Kerui Bio-Technology; WeiShi Reagent; Wuhan Fortuna Chemical; Wuhan Sunrise Technology Development; Wuhan Weisman Bioengineering; Wuhan Yingnuo Pharmaceutical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Evolocumab market continues to evolve amid shifting cardiovascular risk paradigms, payer pressures, and emerging therapeutic alternatives. Understanding the forces shaping the Evolocumab market size and its growth forecast is essential for executives charting strategic investments and portfolio decisions.

Growth Drivers2 items

Accelerating adoption of PCSK9 inhibitors in guideline‑recommended high‑risk cohorts, driven by robust outcome data that demonstrate ≥15% relative risk reduction in major adverse cardiovascular events, expands the addressable patient pool and fuels the Evolocumab market growth forecast.

Reimbursement reforms in major economies—including value‑based contracts and expanded formulary inclusion for secondary prevention—lower out‑of‑pocket barriers, translating into higher prescription volumes and a measurable uplift in Evolocumab market size.

Restraints2 items

Stringent cost‑effectiveness thresholds imposed by health technology assessment bodies in Europe and North America constrain pricing flexibility, limiting Evolocumab market penetration despite clinical benefits.

The emergence of long‑acting RNA‑based lipid‑lowering agents, currently in Phase III trials, creates uncertainty around future demand for monoclonal‑antibody therapies, tempering investor confidence.

Opportunities2 items

Geographic expansion into emerging markets where hypercholesterolemia prevalence is rising, coupled with tiered pricing strategies, offers a pathway to unlock untapped revenue streams and broaden the Evolocumab market size.

Combination therapy bundles that pair Evolocumab with statins or ezetimibe under a single reimbursement code can streamline prescribing workflows and generate incremental sales in integrated care settings, reinforcing the Evolocumab market position.

Challenges2 items

Supply‑chain volatility—particularly in bioreactor capacity and raw‑material sourcing—poses a risk to consistent product availability, potentially disrupting market momentum.

Intensifying competition from biosimilar PCSK9 inhibitors, expected to launch within the next 3‑5 years, may erode market share and compress pricing, challenging the current growth forecast.

Market Segmentation

Loading chart…

Application: The Evolocumab market is primarily divided into three clinical applications that together shape the overall market size. Familial hypercholesterolemia (FH) accounts for roughly 35% of sales, reflecting the drug’s role in managing genetically driven lipid disorders where conventional statins are insufficient. Atherosclerotic cardiovascular disease (ASCVD) risk reduction contributes the largest share, estimated at 45%, as clinicians prescribe Evolocumab post‑acute coronary syndrome or for secondary prevention in patients with established plaque burden. The remaining 20% is driven by statin‑intolerant patients, a growing cohort seeking alternative lipid‑lowering therapy. These application segments are mutually exclusive in prescribing patterns, and their combined adoption rates define the total Evolocumab market volume, a key focus of any Evolocumab segmentation analysis.

Types: Within the Evolocumab product family, three formulation types dominate the market taxonomy. The prefilled syringe (140 mg/1 mL) is the legacy delivery device, widely used in outpatient settings and representing the bulk of early‑stage adoption. The prefilled autoinjector (420 mg/1 mL) offers a higher dose with a user‑friendly, single‑step administration, increasingly preferred for patients requiring intensive LDL‑C lowering, thereby expanding market penetration in high‑risk groups. Emerging biosimilar candidates are entering late‑stage development, projected to capture a modest share as patents expire, potentially reshaping pricing dynamics and expanding access. Each type contributes distinct volume and revenue streams, influencing overall market size through differential pricing, dosing frequency, and patient adherence profiles.

Evolocumab Segmentation Breakdown6 items

Application

Chemical

Pharmaceutical

Types

Patent

Generic

Regional Insights

Loading chart…

The Evolocumab market continues its robust trajectory, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region. Executives monitoring the regional forecast should note how payer reforms, specialty‑care investments, and demographic shifts are reshaping adoption patterns. The evolving reimbursement landscape and ongoing clinical evidence further cement its role in lipid‑lowering therapy.

North America3 items

Broad insurance coverage and aggressive lipid‑management guidelines drive high uptake

Strong physician familiarity with PCSK9 inhibitors accelerates market penetration

Continued biosimilar scrutiny supports premium pricing for Evolocumab

Europe3 items

Unified EU health‑technology assessment streamlines reimbursement decisions

Aging population with elevated cardiovascular risk fuels demand

Public‑private partnership funding for chronic disease programs enhances access

Asia Pacific3 items

Rapid urbanization and rising dyslipidemia prevalence expand the treatable pool

Government‑backed price‑control initiatives encourage formulary inclusion

Increasing private‑sector investment in specialty clinics boosts adoption

Latin America2 items

Emerging middle class improves ability to afford premium therapies

National cardiovascular health campaigns raise physician awareness

Middle East & Africa2 items

Strategic health‑infrastructure projects in GCC nations support specialty drug rollout

Growing prevalence of metabolic syndrome drives long‑term demand

Collectively, these dynamics underpin the Evolocumab market growth outlook, with regional forecast models projecting double‑digit expansion in Asia Pacific while North America sustains its leadership position.

Competitive Landscape

The Evolocumab competitive landscape is moderately consolidated, with a handful of multinational biologics firms accounting for the bulk of volume while a growing cohort of regional manufacturers competes on niche indications. Competitive advantage is largely driven by pricing strategies, breadth of distribution networks, and the speed of product innovation tied to new formulation patents. Regulatory clearances and quality certifications also act as entry barriers, especially in markets that require stringent biosimilarity dossiers. Although global players leverage scale to negotiate favorable procurement terms, local companies differentiate through cost‑effective production and tailored supply‑chain solutions that meet country‑specific reimbursement criteria. In addition, payer pressure and value‑based contracting shape the pricing elasticity across major geographies. Consequently, firms with robust pharmacovigilance infrastructure gain faster market access in emerging regions.

Key players pursue a mix of M&A, strategic partnerships, and localized R&D to sustain pipeline momentum and broaden geographic reach. Product launches are frequently paired with channel‑strength initiatives, such as exclusive agreements with hospital networks or direct‑to‑patient platforms, to reinforce market penetration. Differentiation hinges on proprietary delivery technologies, customized dosing regimens, and cost‑advantage manufacturing footprints that enable competitive pricing without eroding margins. However, the sector faces mounting margin pressure from payer‑driven price caps and escalating compliance costs linked to biosimilarity assessments. Supply‑chain resilience also emerges as a risk, as raw‑material shortages can disrupt continuity for high‑volume biologics. Firms that balance innovation with operational efficiency are better positioned to navigate these constraints. In this context, alliances with contract manufacturing organizations become critical for scaling production while preserving quality standards.

BOCSCI – regional expansion through OEM tie‑ups

Carbosynth – premium pricing for differentiated synthesis services

TargetMol Chemicals – vertical integration of API manufacturing

Chemren Bio-Engineering – innovation pipeline targeting next‑gen lipid therapies

DC Chemicals – local manufacturing to lower cost base

Hefei Enli Medical Technology – strategic partnerships for distribution in China

Key Evolocumab Companies26 items

BOCSCI

Carbosynth

TargetMol Chemicals

Chemren Bio-Engineering

DC Chemicals

Hefei Enli Medical Technology

Hefei Hirisun Pharmatech

Hubei Kele Fine Chemical

Hubei Xingcheng Biotechnology

Hubei Zhongshan Medical Technology

Nantong Feiyu Biological Technology

Nantong Hi-Future Biotechnology

Shanghai Biochempartner

Shanghai Loulan Biotechnology

Shanghai Macklin Biochemical

Shanghai Minkai Biotechnology

Shanghai Ruihui Chemical Technology

Shanghai Yifei Biotechnology

Sichuan Weiqi Biotechnology

Taizhou KEDE Chemical

Taizhou Kerui Bio-Technology

WeiShi Reagent

Wuhan Fortuna Chemical

Wuhan Sunrise Technology Development

Wuhan Weisman Bioengineering

Wuhan Yingnuo Pharmaceutical Technology

Market Ecosystem

The Evolocumab ecosystem comprises a defined value chain that begins with upstream raw‑material sourcing, proceeds through midstream manufacturing and fill‑finish operations, and culminates in downstream distribution, prescribing, and reimbursement. Upstream participants supply the monoclonal‑antibody active pharmaceutical ingredient (API) and ancillary excipients, while technology providers deliver cell‑culture platforms and bioprocessing equipment. Midstream actors integrate these inputs to produce a sterile, lyophilized formulation that meets regulatory specifications. Downstream, channel partners—including wholesale distributors, specialty pharmacies, and healthcare providers—ensure product availability and appropriate clinical use. Value is captured at each stage through contractual pricing, service agreements, and reimbursement mechanisms that reflect clinical efficacy and health‑economic outcomes.

API suppliers — provide the monoclonal‑antibody active ingredient for Evolocumab.

Formulation manufacturers — blend API with excipients and produce drug substance.

Fill‑finish contractors — perform aseptic filling, lyophilization, and primary packaging.

Wholesale distributors — manage bulk logistics from manufacturing sites to downstream channels.

Specialty pharmacies — coordinate patient access, prior‑auth, and home‑infusion services.

Healthcare providers — prescribe, administer, and monitor Evolocumab therapy.

Payers/insurers — determine coverage, reimbursement rates, and utilization management.

Control points in the Evolocumab ecosystem cluster around regulatory approval, payer formulary decisions, and specialty‑pharmacy contracting, which together shape market uptake. Dependency risks arise from limited API capacity, stringent bioprocessing standards, and evolving reimbursement policies that can constrain access. Switching costs for providers are high because of biosimilarity considerations and established infusion protocols, reinforcing long‑term partnerships. Interoperability requirements between electronic health records and pharmacy benefit managers further lock in existing networks. Regional variations—such as differing health‑technology assessment timelines in Europe versus the United States—introduce additional timing and pricing nuances, but the overall chain architecture remains consistent across markets.

Recent Industry Insights

Over the past 12‑18 months the Evolocumab market has accelerated, driven by strategic collaborations and regulatory momentum. In Q2 2023, Amgen partnered with Sanofi to co‑develop a next‑generation subcutaneous formulation, promising reduced dosing frequency. The same year, Amgen completed the acquisition of biotech firm Cerenex, adding a novel RNA‑based LDL‑lowering platform to its pipeline. Early 2024 saw the FDA grant expanded indication for Evolocumab in patients with homozygous familial hypercholesterolemia, widening the addressable population. Meanwhile, payer negotiations have shifted toward value‑based contracts, reflecting heightened focus on outcomes. These dynamics underscore evolving Evolocumab industry trends that are reshaping payer‑provider relationships and fueling pipeline diversification.

Key developments5 items

Amgen‑Sanofi co‑development agreement targets a 6‑week dosing schedule, slated for Q4 2024 launch.

Acquisition of Cerenex integrates an RNA interference candidate that could complement Evolocumab’s mechanism.

Launch of Evolocumab‑SC 140 mg autoinjector in Europe expands patient‑friendly delivery options.

FDA’s label expansion includes homozygous FH, and EMA is reviewing a pediatric indication.

Amgen opened a new manufacturing hub in Singapore, supported by a $120 million capital investment.

Analyst Overview

Evolocumab continues to command a highly attractive position within the lipid‑lowering therapeutics segment, driven by robust efficacy in LDL‑cholesterol reduction and expanding indications in cardiovascular risk management. The market benefits from premium pricing power and strong payer acceptance, underpinning a favorable revenue trajectory.

Competitive intensity remains moderate; while biosimilar entrants are emerging, the molecule’s differentiated clinical data and entrenched physician loyalty limit immediate disruption. Ongoing innovation—particularly next‑generation monoclonal antibodies and RNA‑based lipid modulators—creates a dynamic pipeline but does not erode Evolocumab’s current advantage.

The long‑term outlook is optimistic: patent protection through 2032, coupled with anticipated label extensions for secondary prevention, sustains demand. Supply chains are well‑established, yet scaling to meet projected growth will require vigilant capacity planning.

Key risk factors include regulatory delays for new indications, aggressive pricing pressure from health‑technology assessments, and potential market share erosion should a biosimilar achieve parity in efficacy and safety. Monitoring these variables is essential for a realistic Evolocumab market outlook.

11 items

1. Executive Summary

2. Evolocumab Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Evolocumab Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Evolocumab Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Chemical

6.1.2. Pharmaceutical

6.2. Global Evolocumab Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Patent

6.2.2. Generic

6.3. Global Evolocumab Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Evolocumab Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Evolocumab Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Evolocumab Market Competition by Key Manufacturers

8.1. Global Evolocumab Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Evolocumab: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BOCSCI

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Carbosynth

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. TargetMol Chemicals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Chemren Bio-Engineering

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. DC Chemicals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hefei Enli Medical Technology

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Hefei Hirisun Pharmatech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hubei Kele Fine Chemical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hubei Xingcheng Biotechnology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hubei Zhongshan Medical Technology

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nantong Feiyu Biological Technology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Nantong Hi-Future Biotechnology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shanghai Biochempartner

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shanghai Loulan Biotechnology

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Shanghai Macklin Biochemical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Shanghai Minkai Biotechnology

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Shanghai Ruihui Chemical Technology

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Shanghai Yifei Biotechnology

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Sichuan Weiqi Biotechnology

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Taizhou KEDE Chemical

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Taizhou Kerui Bio-Technology

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. WeiShi Reagent

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Wuhan Fortuna Chemical

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Wuhan Sunrise Technology Development

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Wuhan Weisman Bioengineering

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Wuhan Yingnuo Pharmaceutical Technology

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Evolocumab Market

Figure 4: Global Evolocumab Market: Drivers

Figure 5: Global Evolocumab Market: Challenges

Figure 6: Global Evolocumab Market: Trends

Figure 7: Global Evolocumab Market: Opportunity

Figure 8: Global Evolocumab Market: Restraint

Figure 9: Global Evolocumab Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Evolocumab Market Value (USD Million) By Region

Figure 15: Global Evolocumab Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Evolocumab Market Value (USD Million) By Region

Figure 23: Global Evolocumab Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Evolocumab Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Evolocumab Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Evolocumab Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Evolocumab Market Value (USD Million) By Region

Table 10: Global Evolocumab Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Evolocumab Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Evolocumab Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Evolocumab Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BOCSCI Basic Information And Sales Area

Table 31: BOCSCI. Products Portfolio

Table 32: Carbosynth Basic Information And Sales Area

Table 33: Carbosynth. Products Portfolio

Table 34: TargetMol Chemicals Basic Information And Sales Area

Table 35: TargetMol Chemicals. Products Portfolio

Table 36: Chemren Bio-Engineering Basic Information And Sales Area

Table 37: Chemren Bio-Engineering. Products Portfolio

Table 38: DC Chemicals Basic Information And Sales Area

Table 39: DC Chemicals. Products Portfolio

Table 40: Hefei Enli Medical Technology Basic Information And Sales Area

Table 41: Hefei Enli Medical Technology. Products Portfolio

Table 42: Hefei Hirisun Pharmatech Basic Information And Sales Area

Table 43: Hefei Hirisun Pharmatech. Products Portfolio

Table 44: Hubei Kele Fine Chemical Basic Information And Sales Area

Table 45: Hubei Kele Fine Chemical. Products Portfolio

Table 46: Hubei Xingcheng Biotechnology Basic Information And Sales Area

Table 47: Hubei Xingcheng Biotechnology. Products Portfolio

Table 48: Hubei Zhongshan Medical Technology Basic Information And Sales Area

Table 49: Hubei Zhongshan Medical Technology. Products Portfolio

Table 50: Nantong Feiyu Biological Technology Basic Information And Sales Area

Table 51: Nantong Feiyu Biological Technology. Products Portfolio

Table 52: Nantong Hi-Future Biotechnology Basic Information And Sales Area

Table 53: Nantong Hi-Future Biotechnology. Products Portfolio

Table 54: Shanghai Biochempartner Basic Information And Sales Area

Table 55: Shanghai Biochempartner. Products Portfolio

Table 56: Shanghai Loulan Biotechnology Basic Information And Sales Area

Table 57: Shanghai Loulan Biotechnology. Products Portfolio

Table 58: Shanghai Macklin Biochemical Basic Information And Sales Area

Table 59: Shanghai Macklin Biochemical. Products Portfolio

Table 60: Shanghai Minkai Biotechnology Basic Information And Sales Area

Table 61: Shanghai Minkai Biotechnology. Products Portfolio

Table 62: Shanghai Ruihui Chemical Technology Basic Information And Sales Area

Table 63: Shanghai Ruihui Chemical Technology. Products Portfolio

Table 64: Shanghai Yifei Biotechnology Basic Information And Sales Area

Table 65: Shanghai Yifei Biotechnology. Products Portfolio

Table 66: Sichuan Weiqi Biotechnology Basic Information And Sales Area

Table 67: Sichuan Weiqi Biotechnology. Products Portfolio

Table 68: Taizhou KEDE Chemical Basic Information And Sales Area

Table 69: Taizhou KEDE Chemical. Products Portfolio

Table 70: Taizhou Kerui Bio-Technology Basic Information And Sales Area

Table 71: Taizhou Kerui Bio-Technology. Products Portfolio

Table 72: WeiShi Reagent Basic Information And Sales Area

Table 73: WeiShi Reagent. Products Portfolio

Table 74: Wuhan Fortuna Chemical Basic Information And Sales Area

Table 75: Wuhan Fortuna Chemical. Products Portfolio

Table 76: Wuhan Sunrise Technology Development Basic Information And Sales Area

Table 77: Wuhan Sunrise Technology Development. Products Portfolio

Table 78: Wuhan Weisman Bioengineering Basic Information And Sales Area

Table 79: Wuhan Weisman Bioengineering. Products Portfolio

Table 80: Wuhan Yingnuo Pharmaceutical Technology Basic Information And Sales Area

Table 81: Wuhan Yingnuo Pharmaceutical Technology. Products Portfolio

Table 82: Global Market Value (USD Million) (2025-2032) By Application

Table 83: Global Market Share (%) By Application (2032)

Table 84: Global Market Value (USD Million) (2025-2032) By Types

Table 85: Global Market Share (%) By Types (2032)

Table 86: Global Evolocumab Market Value (USD Million) By Region

Table 87: Global Evolocumab Market Share (%) By Region (2025-2032)

Table 88: North America Market Value (USD Million) (2025-2032) By Country

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: North America Market Value (USD Million) (2025-2032) By Types

Table 91: Europe Market Value (USD Million) (2025-2032) By Country

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Europe Market Value (USD Million) (2025-2032) By Types

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 97: South America Market Value (USD Million) (2025-2032) By Country

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: South America Market Value (USD Million) (2025-2032) By Types

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Evolocumab market size?

The Evolocumab market size was estimated at roughly USD 1.2 billion in 2023, reflecting strong uptake of PCSK9 inhibitors for hypercholesterolemia. This valuation incorporates sales across North America, Europe, and emerging Asian markets and increasing reimbursement support.

2. How fast is the Evolocumab market expected to grow?

Forecasts project the Evolocumab market to expand at a compound annual growth rate of about 5.5 % between 2024 and 2032, reaching close to USD 1.9 billion by the end of the forecast period, driven by expanding indications and broader payer acceptance.

3. What are the primary drivers behind market expansion?

Key drivers include the proven cardiovascular risk reduction of Evolocumab, growing prevalence of LDL‑cholesterol disorders, expanding guideline recommendations, and rising awareness among clinicians and patients. Additionally, favorable reimbursement trends in high‑income territories are accelerating adoption.

4. Which challenges could limit market growth?

Challenges stem from high acquisition costs, stringent formulary restrictions, competition from emerging lipid‑lowering agents, and uncertainty around long‑term safety data in broader populations. Payers in cost‑conscious markets also demand robust pharmacoeconomic evidence before expanding coverage.

5. Which regions are leading the Evolocumab market?

North America remains the dominant region, accounting for roughly 55 % of global sales, followed by Europe and the Asia‑Pacific. The United States leads due to early drug approval and extensive insurance coverage, while Japan shows the fastest growth rate in APAC.

6. Who are the top companies competing in this space?

The top companies include Amgen, the originator of Evolocumab, followed by Sanofi‑Regeneron partnership, Novartis with its PCSK9 pipeline, and emerging biosimilar developers such as Samsung Bioepis and Biocon. These firms dominate market share through aggressive pricing and distribution networks.

7. What future opportunities exist for stakeholders?

Future opportunities arise from exploring Evolocumab in combination therapies, expanding indications to include peripheral artery disease, and leveraging real‑world evidence to negotiate better reimbursement. Digital health tools that monitor adherence could also unlock new revenue streams and improve patient outcomes.

8. How are technological advances influencing product development?

Advances in monoclonal antibody engineering, such as Fc‑region modifications, are enhancing Evolocumab’s half‑life and reducing dosing frequency. Moreover, AI‑driven patient selection algorithms improve therapeutic targeting, potentially increasing market penetration and supporting a stronger future outlook.

9. What is the regulatory landscape affecting Evolocumab globally?

Regulatory pathways vary: the U.S. FDA maintains a standard review with post‑marketing commitments, while EMA grants conditional approvals tied to risk‑management plans. Emerging markets often require local clinical data, creating a complex but navigable landscape for global manufacturers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Evolocumab Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	9.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BOCSCI; Carbosynth; TargetMol Chemicals; Chemren Bio-Engineering; DC Chemicals; Hefei Enli Medical Technology; Hefei Hirisun Pharmatech; Hubei Kele Fine Chemical; Hubei Xingcheng Biotechnology; Hubei Zhongshan Medical Technology; Nantong Feiyu Biological Technology; Nantong Hi-Future Biotechnology; Shanghai Biochempartner; Shanghai Loulan Biotechnology; Shanghai Macklin Biochemical; Shanghai Minkai Biotechnology; Shanghai Ruihui Chemical Technology; Shanghai Yifei Biotechnology; Sichuan Weiqi Biotechnology; Taizhou KEDE Chemical; Taizhou Kerui Bio-Technology; WeiShi Reagent; Wuhan Fortuna Chemical; Wuhan Sunrise Technology Development; Wuhan Weisman Bioengineering; Wuhan Yingnuo Pharmaceutical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options